Difference between revisions of "Template:Glutamate receptor modulators"

From blackwiki
Jump to navigation Jump to search
imported>Meodipt
imported>Medgirl131
(Replaced content with '{{Navboxes | title = Glutamate receptor modulators | titlestyle = background:#ccccff | state = {{{state<includeonly>|collapsed<...')
 
(139 intermediate revisions by 32 users not shown)
Line 1: Line 1:
{{Navbox
+
{{Navboxes
| name = Glutamatergics
+
  | title = [[Glutamate receptor]] [[receptor modulator|modulator]]s
| title = [[Glutamate]]rgics
+
  | titlestyle = background:#ccccff
| groupstyle = background: LightYellow
+
| state = {{{state<includeonly>|collapsed</includeonly>}}}
| state = collapsed
+
| list1 =  
 
+
{{Ionotropic glutamate receptor modulators}}
  | group1 = [[Ionotropic]]
+
{{Metabotropic glutamate receptor modulators}}
  | list1  = {{Navbox subgroup
+
}}<noinclude>
  | groupstyle = background: LightYellow
+
{{collapsible option}}
 
+
[[Category:Drug templates by receptor, channel, or pump]]
    | group1 = [[AMPA receptor|AMPA]]
 
    | list1  = '''[[Ampakine|Agonists]]:''' [[5-Fluorowillardiine]]{{•}} [[AMPA]]{{•}} [[Domoic acid]]{{•}} [[Quisqualic acid]]; ''[[Positive allosteric modulator]]s:'' [[Aniracetam]]{{•}} [[Cyclothiazide]]{{•}} [[CX-516]]{{•}} [[CX-546]]{{•}} [[CX-614]]{{•}} [[CX-691]]{{•}} [[CX-717]]{{•}} [[Diazoxide]]{{•}} [[Hydrochlorothiazide|HCTZ]]{{•}} [[IDRA-21]]{{•}} [[LY-392,098]]{{•}} [[LY-404,187]]{{•}} [[LY-451,395]]{{•}} [[LY-451,646]]{{•}} [[LY-503,430]]{{•}} [[Oxiracetam]]{{•}} [[PEPA (drug)|PEPA]]{{•}} [[Piracetam]]{{•}} [[Pramiracetam]]{{•}} [[S-18986]]{{•}} [[Sunifiram]]{{•}} [[Unifiram]]<br/>'''Antagonists:''' [[ATPO]]{{•}} [[Barbiturates]]{{•}} [[Caroverine]]{{•}} [[CNQX]]{{•}} [[DNQX]]{{•}} [[GYKI-52466]]{{•}} [[NBQX]]{{•}} [[Perampanel]]{{•}} [[Talampanel]]{{•}} [[Tezampanel]]{{•}} [[Topiramate]]; ''[[Negative allosteric modulator]]s:'' [[GYKI-53,655]]
 
 
 
    | group2 = [[NMDA receptor|NMDA]]
 
    | list2  = '''Agonists:''' ''Glutamate/acite site competitive agonists'': [[Aspartate]]{{•}} [[Glutamate]]{{•}} [[Homoquinolinic acid]]{{•}} [[Ibotenic acid]]{{•}} [[NMDA]]{{•}} [[Quinolinic acid]]{{•}} [[Tetrazolylglycine]]; ''Glycine site agonists:'' [[ACBD (drug)|ACBD]]{{•}} [[ACPC]]{{•}} [[ACPD]]{{•}} [[Alanine]]{{•}} [[Carboxycyclopropylglycine|CCG]]{{•}} [[Cycloserine]]{{•}} [[N-(3,3-Diphenylpropyl)glycinamide|DHPG]]{{•}} [[Fluoroalanine]]{{•}} [[Glycine]]{{•}} [[HA-966]]{{•}} [[L-687,414]]{{•}} [[Milacemide]]{{•}} [[Sarcosine]]{{•}} [[Serine]]{{•}} [[Tetrazolylglycine]]; ''Polyamine site agonists:'' [[Acamprosate]]{{•}} [[Spermidine]]{{•}} [[Spermine]]<br/>'''[[NMDA receptor antagonist|Antagonists]]:''' ''Competitive antagonists:'' [[AP5|AP5 (APV)]]{{•}} [[AP-7 (drug)|AP7]]{{•}} [[CGP-37849]]{{•}} [[CGP-39551]]{{•}} [[CGP-39653]]{{•}} [[CGP-40116]]{{•}} [[CGS-19755]]{{•}} [[3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid|CPP]]{{•}} [[LY-233,053]]{{•}} [[LY-235,959]]{{•}} [[LY-274,614]]{{•}} [[MDL-100,453]]{{•}} [[Midafotel|Midafotel (d-CPPene)]]{{•}} [[NPC-12,626]]{{•}} [[NPC-17,742]]{{•}} [[PBPD]]{{•}} [[PEAQX]]{{•}} [[Perzinfotel]]{{•}} [[cis-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid|PPDA]]{{•}} [[SDZ-220581]]{{•}} [[Selfotel]]; ''Noncompetitive antagonists:'' [[ARR-15,896]]{{•}} [[Caroverine]]{{•}} [[Dexanabinol]]{{•}} [[FPL-12495]]{{•}} [[FR-115,427]]{{•}} [[Hodgkinsine]]{{•}} [[Magnesium]]{{•}} [[MDL-27,266]]{{•}} [[NPS-1506]]{{•}} [[Psychotridine]]{{•}} [[Zinc]]; ''Uncompetitive pore blockers:'' [[2-MDP]]{{•}} [[3-MeO-PCP]]{{•}} [[8a-Phenyldecahydroquinoline|8A-PDHQ]]{{•}} [[Amantadine]]{{•}} [[Aptiganel]]{{•}} [[ARL-12,495]]{{•}} [[ARL-15,896-AR]]{{•}} [[ARL-16,247]]{{•}} [[Budipine]]{{•}} [[Delucemine]]{{•}} [[Dexoxadrol]]{{•}} [[Dextrallorphan]]{{•}} [[Dieticyclidine]]{{•}} [[Dizocilpine]]{{•}} [[Endopsychosin]]{{•}} [[Esketamine]]{{•}} [[Etoxadrol]]{{•}} [[Eticyclidine]]{{•}} [[Gacyclidine]]{{•}} [[Ibogaine]]{{•}} [[Indantadol]]{{•}} [[Ketamine]]{{•}} [[Ketobemidone]]{{•}} [[Loperamide]]{{•}} [[Memantine]]{{•}} [[Meperidine|Meperidine (Pethidine)]]{{•}} [[Methadone]]{{•}} [[Methorphan]] ([[Dextromethorphan]], [[Levomethorphan]]){{•}} [[Methoxetamine]]{{•}} [[Milnacipran]]{{•}} [[Morphanol]] ([[Dextrorphan]], [[Levorphanol]]){{•}} [[NEFA (drug)|NEFA]]{{•}} [[Neramexane]]{{•}} [[Nitrous oxide]]{{•}} [[Noribogaine]]{{•}} [[Orphenadrine]]{{•}} [[PCPr]]{{•}} [[Phencyclamine]]{{•}} [[Phencyclidine]]{{•}} [[Propoxyphene]]{{•}} [[Remacemide]]{{•}} [[Rhynchophylline]]{{•}} [[Riluzole]]{{•}} [[Rimantadine]]{{•}} [[Rolicyclidine]]{{•}} [[Sabeluzole]]{{•}} [[Tenocyclidine]]{{•}} [[Tiletamine]]{{•}} [[Tramadol]]{{•}} [[Xenon]]; ''Glycine site antagonists:'' [[ACEA-1021]]{{•}} [[ACEA-1328]]{{•}} [[1-Aminocyclopropanecarboxylic acid|ACPC]]{{•}} [[Carisoprodol]]{{•}} [[CGP-39653]]{{•}} [[7-Chlorokynurenate|CKA]]{{•}} [[DCKA]]{{•}} [[Felbamate]]{{•}} [[Gavestinel]]{{•}} [[GV-196,771]]{{•}} [[Kynurenic acid]]{{•}} [[L-689,560]]{{•}} [[L-701,324]]{{•}} [[Lacosamide]]{{•}} [[Licostinel]]{{•}} [[LU-73,068]]{{•}} [[MDL-105,519]]{{•}} [[Meprobamate]]{{•}} [[MRZ 2/576]]{{•}} [[PNQX]]{{•}} [[ZD-9379]]; ''NR2B subunit antagonists:'' [[Besonprodil]]{{•}} [[CO-101,244|CO-101,244 (PD-174,494)]]{{•}} [[CP-101,606]]{{•}} [[Eliprodil]]{{•}} [[Haloperidol]]{{•}} [[Ifenprodil]]{{•}} [[Isoxsuprine]]{{•}} [[Nylidrin]]{{•}} [[Ro8-4304]]{{•}} [[Ro25-6981]]{{•}} [[Traxoprodil]]; ''Polyamine site antagonists:'' [[Arcaine]]{{•}} [[Co 101676]]{{•}} [[1,3-Diaminopropane|Diaminopropane]]{{•}} [[Diethylenetriamine]]{{•}} [[Huperzine A]]{{•}} [[Putrescine]]{{•}} [[Ro 25-6981]]; ''Unclassified/unsorted antagonists:'' [[Chloroform]]{{•}} [[Diethyl ether]]{{•}} [[Enflurane]]{{•}} [[Ethanol|Ethanol (Alcohol)]]{{•}} [[Halothane]]{{•}} [[Isoflurane]]{{•}} [[Methoxyflurane]]{{•}} [[Toluene]]{{•}} [[1,1,1-Trichloroethane|Trichloroethane]]{{•}} [[2,2,2-Trichloroethanol|Trichloroethanol]]{{•}} [[Trichloroethylene]]{{•}} [[Xylene]]
 
 
 
    | group3 = [[Kainate receptor|Kainate]]
 
    | list3  = '''Agonists:''' [[5-Iodowillardiine]]{{•}} [[ATPA]]{{•}} [[Domoic acid]]{{•}} [[Kainic acid]]{{•}} [[LY-339,434]]{{•}} [[SYM-2081]]<br/>'''Antagonists:''' [[CNQX]]{{•}} [[DNQX]]{{•}} [[LY-382,884]]{{•}} [[NBQX]]{{•}} [[NS102]]{{•}} [[Tezampanel]]{{•}} [[Topiramate]]{{•}} [[UBP-302]]; ''Negative allosteric modulators:'' [[NS-3763]]
 
 
 
    }}
 
 
 
  | group2 = [[Metabotropic glutamate receptor|Metabotropic]]
 
  | list2 = {{Navbox subgroup
 
  | groupstyle = background: LightYellow
 
 
 
    | group1 = [[Metabotropic_glutamate_receptor#Group_I|Group I]]
 
    | list1  = '''Agonists:''' ''Unselective:'' [[ACPD]]{{•}} [[Dihydroxyphenylglycine|DHPG]]{{•}} [[Quisqualic acid]]; ''mGlu1-selective:'' [[Ro01-6128]]{{•}} [[Ro67-4853]]{{•}} [[Ro67-7476]]{{•}} [[VU-71]]; ''mGlu5-selective:'' [[ADX-47273]]{{•}} [[CDPPB]]{{•}} [[CHPG]]{{•}} [[1-(3-fluorophenyl)-N-((3-fluorophenyl)methylideneamino)methanimine|DFB]]{{•}} [[VU-1545]]<br/>'''Antagonists:''' ''Unselective:'' [[MCPG]]{{•}} [[NPS-2390]]; ''mGlu1-selective:'' [[BAY 36-7620]]{{•}} [[CPCCOEt]]{{•}} [[LY-367,385]]{{•}} [[LY-456,236]]; ''mGlu5-selective:'' [[DMeOB]]{{•}} [[Fenobam]]{{•}} [[LY-344,545]]{{•}} [[2-Methyl-6-(phenylethynyl)pyridine|MPEP]]{{•}} [[MTEP]]{{•}} [[SIB-1757]]{{•}} [[SIB-1893]]
 
 
 
    | group2 = [[Metabotropic_glutamate_receptor#Group_II_.26_Group_III|Group II]]
 
    | list2  = '''Agonists:''' ''Unselective:'' [[CBiPES]]{{•}} [[DCG-IV]]{{•}} [[Eglumegad]]{{•}} [[LY-379,268]]{{•}} [[LY-404,039]]{{•}} [[LY-487,379]]{{•}} [[MGS-0028]]; ''mGlu2-selective:'' [[Biphenylindanone A|BINA]]{{•}} [[LY-566,332]]<br/>'''Antagonists:''' ''Unselective:'' [[APICA (drug)|APICA]]{{•}} [[EGLU]]{{•}} [[HYDIA]]{{•}} [[LY-307,452]]{{•}} [[LY-341,495]]{{•}} [[MCPG]]{{•}} [[MGS-0039]]: ''mGlu2-selective:'' [[PCCG-4]]; ''mGlu3-selective:'' [[CECXG]]
 
 
 
    | group3 = [[Metabotropic_glutamate_receptor#Group_II_.26_Group_III|Group III]]
 
    | list3  = '''Agonists:''' ''Unselective:'' [[L-AP4]]; ''mGlu4-selective:'' [[PHCCC]]{{}} [[VU-001,171]]{{}} [[VU-0155,041]]; ''mGlu7-selective:'' [[AMN082]]; ''mGlu8-selective:'' [[DCPG]]<br/>'''Antagonists:''' ''Unselective:'' [[CPPG]]{{•}} [[MAP4 (drug)|MAP4]]{{•}} [[MSOP (drug)|MSOP]]{{•}} [[MPPG]]{{•}} [[MTPG]]{{•}} [[UBP-1112]]; ''mGlu7-selective:'' [[MMPIP]]
 
 
 
    }}
 
 
 
  | group3 = [[Glutamate transporter|Transporter]]<br>[[Reuptake inhibitor|inhibitor]]s
 
  |  list3 = {{Navbox subgroup
 
  | groupstyle = background: LightYellow
 
 
 
    | group1 = [[Glutamate transporter|EAAT]]s
 
    |  list1 = [[Dihydrokainic acid|DHKA]]{{•}} [[L-trans-Pyrrolidine-2,4-dicarboxylic acid|PDC]]{{}} [[WAY-213,613]]
 
 
 
    | group2 = [[Vesicular glutamate transporters|vGluTs]]
 
    |  list2 = [[7-Chlorokynurenic acid|7-CKA]]{{•}} [[Evans blue]]
 
 
 
  }}
 
 
 
}}
 
<noinclude>
 
[[Category:Drug templates by receptor, channel, or pump|{{PAGENAME}}]]
 
 
</noinclude>
 
</noinclude>

Latest revision as of 10:57, 27 August 2017

Template:Navboxes Initial visibility: currently defaults to autocollapse

To set this template's initial visibility, the |state= parameter may be used:

  • |state=collapsed: {{Glutamate receptor modulators|state=collapsed}} to show the template collapsed, i.e., hidden apart from its title bar
  • |state=expanded: {{Glutamate receptor modulators|state=expanded}} to show the template expanded, i.e., fully visible
  • |state=autocollapse: {{Glutamate receptor modulators|state=autocollapse}}
    • shows the template collapsed to the title bar if there is a {{navbar}}, a {{sidebar}}, or some other table on the page with the collapsible attribute
    • shows the template in its expanded state if there are no other collapsible items on the page

If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.